Uncategorized

The Hatch-Waxman Playbook: Paragraph IV Certifications, 180-Day Exclusivity, and the $467 Billion Generic Drug Race

Generic drugs are in a race—and the rules of the track are changing.
If you’ve ever wondered why some generic launches feel like clockwork while others get delayed for years, the answer is often buried in the fine print of the Hatch-Waxman Act. In a re…

The Hatch-Waxman Playbook: Paragraph IV Certifications, 180-Day Exclusivity, and the $467 Billion Generic Drug Race Read Post »

Biotechblog
Scroll to Top